Zentalis Pharmaceuticals (ZNTL) Institutional Ownership $4.06 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.00 -0.06 (-1.38%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Zentalis Pharmaceuticals (NASDAQ:ZNTL)Number ofInstitutional Buyers(last 12 months)49TotalInstitutional Inflows(last 12 months)$19.25MNumber ofInstitutional Sellers(last 12 months)34TotalInstitutional Outflows(last 12 months)$16.53M Get ZNTL Insider Trade Alerts Want to know when executives and insiders are buying or selling Zentalis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ZNTL Institutional Buying and Selling by Quarter Zentalis Pharmaceuticals Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/21/2026 CTC Alternative Strategies Ltd.12,500$29K0.1%N/A0.018% 5/19/2026 Bank of America Corp DE1,132,294$2.65M0.0%-17.2%1.591% 5/19/2026 RBF Capital LLC50,000$117K0.0%-37.5%0.070% 5/18/2026 ADAR1 Capital Management LLC144,636$338K0.0%+80.8%0.203% 5/15/2026 OMERS ADMINISTRATION Corp47,700$112K0.0%N/A0.067% 5/14/2026 Renaissance Technologies LLC1,938,145$4.54M0.0%-32.8%2.723% 5/14/2026 Sei Investments Co.191,551$448K0.0%+14.6%0.269% 5/14/2026 State of Wyoming28,466$67K0.0%N/A0.040% 5/7/2026 Dimensional Fund Advisors LP272,034$634K0.0%+182.6%0.382% 4/27/2026 Private Advisor Group LLC31,472$74K0.0%N/A0.044% Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/19/2026 Invesco Ltd.188,582$255K0.0%+8.6%0.261% 2/18/2026 XTX Topco Ltd576,707$779K0.0%+5.1%0.798% 2/18/2026 Quadrature Capital Ltd137,568$186K0.0%+126.8%0.190% 2/18/2026 Opaleye Management Inc.1,400,906$1.89M0.2%+342.6%1.939% 2/18/2026 Millennium Management LLC673,129$909K0.0%-25.4%0.932% 2/18/2026 Ishara Investments LP1,320,000$1.78M2.1%N/A1.827% 2/18/2026 5AM Venture Management LLC3,947,913$5.33M1.7%+705.7%5.464% 2/17/2026 ADAR1 Capital Management LLC80,000$108K0.0%+60.0%0.111% 2/17/2026 Almitas Capital LLC610,073$824K0.2%+33.4%0.844% 2/17/2026 AQR Capital Management LLC45,995$62K0.0%-57.0%0.064% 2/17/2026 Graham Capital Management L.P.90,910$123K0.0%-40.2%0.126% 2/17/2026 Opal Capital LLC72,251$98K0.0%N/A0.100% 2/16/2026 Squarepoint Ops LLC107,734$145K0.0%+405.3%0.149% 2/16/2026 Panagora Asset Management Inc.86,640$117K0.0%-11.5%0.120% 2/16/2026 Barclays PLC568,443$767K0.0%+252.0%0.787% 2/13/2026 Marshall Wace LLP247,788$335K0.0%N/A0.343% 2/13/2026 Walleye Capital LLC110,448$149K0.0%-8.3%0.153% 2/13/2026 Quarry LP132,000$178K0.0%+21.4%0.183% 2/12/2026 Jane Street Group LLC473,175$639K0.0%-26.7%0.655% 2/12/2026 Carson Advisory Inc.23,470$32K0.0%-26.8%0.032% 2/12/2026 Renaissance Technologies LLC2,883,745$3.89M0.0%+24.0%3.991% 2/12/2026 Dimensional Fund Advisors LP96,263$130K0.0%-48.0%0.133% 2/12/2026 Federated Hermes Inc.34,574$47K0.0%-15.9%0.048% 2/11/2026 Primecap Management Co. CA957,420$1.29M0.0%-0.5%1.325% 2/10/2026 Sivia Capital Partners LLC20,000$27K0.0%N/A0.028% 2/10/2026 Goldman Sachs Group Inc.118,212$160K0.0%-65.8%0.164% 2/6/2026 GSA Capital Partners LLP1,169,573$1.58M0.1%+8.5%1.619% 2/5/2026 Barr E S & Co.57,500$78K0.0%+43.8%0.080% 2/4/2026 49 Wealth Management LLC70,911$96K0.0%+151.5%0.098% 2/3/2026 Anfield Capital Management LLC242,605$328K0.1%+239.9%0.336% Your book is inside (Ad)The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.Download your copy now.1/28/2026 Peapod Lane Capital LLC448,861$606K0.5%-20.6%0.621% 1/8/2026 Wealth Enhancement Advisory Services LLC130,407$176K0.0%-21.6%0.180% 1/1/2026 JPMorgan Chase & Co.723,075$1.09M0.0%+31.4%1.001% 11/17/2025 Jacobs Levy Equity Management Inc.700,576$1.06M0.0%-18.3%0.970% 11/17/2025 XTX Topco Ltd548,629$828K0.0%+107.2%0.759% 11/17/2025 Voleon Capital Management LP27,161$41K0.0%N/A0.038% 11/17/2025 Qube Research & Technologies Ltd56,639$86K0.0%+76.4%0.078% 11/17/2025 Millennium Management LLC902,521$1.36M0.0%-74.0%1.249% 11/17/2025 Bank of America Corp DE1,548,781$2.34M0.0%+117.1%2.144% 11/17/2025 Almitas Capital LLC457,322$691K0.2%-71.4%0.633% 11/17/2025 Algert Global LLC48,496$73K0.0%N/A0.067% 11/17/2025 Ameriprise Financial Inc.52,572$79K0.0%-42.4%0.073% 11/14/2025 Creative Planning260,000$393K0.0%+757.0%0.360% 11/14/2025 Two Sigma Investments LP1,363,347$2.06M0.0%+24.7%1.887% 11/14/2025 Squarepoint Ops LLC21,322$32K0.0%-54.1%0.030% 11/13/2025 UBS Group AG532,678$804K0.0%+311.4%0.738% 11/13/2025 BNP Paribas Financial Markets158,935$240K0.0%-8.4%0.220% 11/12/2025 Dimensional Fund Advisors LP185,032$279K0.0%-44.9%0.256% 11/12/2025 Primecap Management Co. CA962,620$1.45M0.0%-6.3%1.334% 11/7/2025 GSA Capital Partners LLP1,077,656$1.63M0.1%-4.9%1.494% 11/7/2025Vanguard Group Inc.2,904,400$4.39M0.0%+0.7%4.026% 11/7/2025 JPMorgan Chase & Co.723,075$1.09M0.0%+31.4%1.002% 11/6/2025Tybourne Capital Management HK Ltd.961,486$1.45M4.7%-35.0%1.333% 11/5/2025 Savant Capital LLC16,521$25K0.0%-67.4%0.023% 10/29/2025 Wealth Enhancement Advisory Services LLC166,290$258K0.0%-4.4%0.231% 10/23/2025 SG Americas Securities LLC31,579$48K0.0%+35.3%0.044% 9/26/2025 Corient Private Wealth LLC35,760$41K0.0%N/A0.050% 8/19/2025 State of Wyoming73,797$86K0.0%+63.4%0.102% 8/15/2025 Corient Private Wealth LLC71,520$83K0.0%N/A0.099% 8/15/2025 Opaleye Management Inc.1,924,300$2.23M0.5%-3.1%2.667% 8/15/2025 Man Group plc406,344$471K0.0%+302.3%0.563% 8/15/2025 BNP Paribas Financial Markets173,484$201K0.0%+145.0%0.240% 8/15/2025 Bridgeway Capital Management LLC77,300$90K0.0%-49.2%0.107% 8/15/2025 Balyasny Asset Management L.P.970,862$1.13M0.0%N/A1.346% 8/15/2025 Bank of America Corp DE713,315$827K0.0%-36.9%0.989% 8/15/2025 Ameriprise Financial Inc.91,195$106K0.0%+622.8%0.126% 8/14/2025 Jane Street Group LLC664,061$770K0.0%+346.3%0.921% 8/14/2025 Sei Investments Co.167,100$194K0.0%+373.1%0.232% 8/14/2025 RBF Capital LLC80,000$93K0.0%N/A0.111% 8/14/2025 Qube Research & Technologies Ltd32,113$37K0.0%N/A0.045% 8/14/2025 Federated Hermes Inc.39,736$46K0.0%-94.7%0.055% 8/13/2025 Walleye Capital LLC129,867$151K0.0%-62.0%0.180% 8/13/2025 Decheng Capital LLC1,323,327$1.54M0.4%-34.5%1.834% 8/13/2025 Stonepine Capital Management LLC109,010$126K0.1%+81.7%0.151% 8/13/2025 Quadrature Capital Ltd52,456$61K0.0%N/A0.073% 8/12/2025 XTX Topco Ltd264,829$307K0.0%+112.9%0.367% 8/12/2025 JPMorgan Chase & Co.550,447$639K0.0%-26.3%0.763% 8/12/2025 Catalyst Funds Management Pty Ltd26,800$31K0.0%N/A0.037% 8/11/2025 Primecap Management Co. CA1,027,620$1.19M0.0%-18.7%1.428% 8/8/2025 Creative Planning30,340$35K0.0%-87.2%0.042% Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.8/8/2025 Geode Capital Management LLC618,167$717K0.0%-54.4%0.859% 8/7/2025 49 Wealth Management LLC21,546$25K0.0%-52.7%0.030% 8/7/2025 Acadian Asset Management LLC2,799,020$3.24M0.0%+4.7%3.890% 8/7/2025 Connor Clark & Lunn Investment Management Ltd.314,845$365K0.0%-12.8%0.438% 8/6/2025 Savant Capital LLC50,727$59K0.0%N/A0.071% 8/1/2025 Y Intercept Hong Kong Ltd32,740$38K0.0%N/A0.046% 8/1/2025Tybourne Capital Management HK Ltd.1,478,152$1.72M5.0%+53.7%2.054% 7/25/2025 CWM LLC28,646$33K0.0%-27.8%0.040% 7/15/2025 Public Employees Retirement System of Ohio36,700$43K0.0%+351.7%0.051% 7/10/2025 Wealth Enhancement Advisory Services LLC174,006$219K0.0%-25.7%0.242% ZNTL Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ZNTL shares? During the previous two years, 127 institutional investors and hedge funds held shares of Zentalis Pharmaceuticals. The most heavily invested institutionals were FMR LLC ($18.68M), Verition Fund Management LLC ($5.54M), 5AM Venture Management LLC ($5.33M), State Street Corp ($4.59M), Renaissance Technologies LLC ($4.54M), Vanguard Group Inc. ($4.39M), and D. E. Shaw & Co. Inc. ($3.76M).Learn more on Zentalis Pharmaceuticals' institutional investors. Which institutional investors have been buying Zentalis Pharmaceuticals' stock? Of the 112 institutional investors that purchased Zentalis Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: 5AM Venture Management LLC ($3.46M), Millennium Management LLC ($2.18M), Acadian Asset Management LLC ($1.73M), Ishara Investments LP ($1.32M), Opaleye Management Inc. ($1.28M), Integral Health Asset Management LLC ($1.05M), and Balyasny Asset Management L.P. ($970.86K). How much institutional buying is happening at Zentalis Pharmaceuticals? Institutional investors have bought a total of 14,159,146 shares in the last 24 months. This purchase volume represents approximately $19.25M in transactions. Which of Zentalis Pharmaceuticals' major shareholders have been selling company stock? Of the 34 institutional investors that sold Zentalis Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Millennium Management LLC ($2.80M), Almitas Capital LLC ($1.14M), Renaissance Technologies LLC ($945.60K), Geode Capital Management LLC ($737.50K), Federated Hermes Inc. ($719.33K), Decheng Capital LLC ($696.44K), and Goldman Sachs Group Inc. ($688.66K). How much institutional selling is happening at Zentalis Pharmaceuticals? Institutional investors have sold a total of 11,218,957 shares in the last 24 months. This volume of shares sold represents approximately $16.53M in transactions. Related Companies JBIO Institutional Ownership COLL Institutional Ownership XERS Institutional Ownership MRVI Institutional Ownership CVAC Institutional Ownership CRVS Institutional Ownership SVRA Institutional Ownership ALVO Institutional Ownership CRON Institutional Ownership CGEM Institutional Ownership This page (NASDAQ:ZNTL) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
